As prescription drug spending is on the rise in China, coverage decisions are becoming increasingly important and more complex with the advent of new of high-cost, high-reward therapeutics. In a new article in The BMJ, learn more about the role that real-world evidence (RWE) is playing in the reimbursement decision-making process.
According to the authors, “Substantial challenges arise in assessing the value of drugs to inform coverage decisions. One problem is inadequate clinical evidence. Traditionally, the assessment process largely relies on evidence derived from randomised controlled trials, which are typically designed with strict patient selection criteria, implemented with reinforced compliance to treatments, and have relatively short follow-up. The drug performance in randomised trials may differ from that in the real world. Furthermore, the trials are often multicentre international trials in populations that might not fully represent the Chinese population.”
To read more, click here.
(Source: The BMJ, June 15th, 2023)